ArticleFrontiers in oncology2026
Perioperative outcomes and prognostic determinants in adult spindle cell/sclerosing rhabdomyosarcoma: implications of treatment intensity, surgical margins, and molecular heterogeneity.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spindle cell/sclerosing rhabdomyosarcoma (ssRMS) represents an uncommon and biologically heterogeneous soft tissue sarcoma with clinical outcomes in adults markedly inferior to those in pediatric populations. Perioperative treatment strategies and prognostic factors specific to adult ssRMS remain poorly defined. Methods: A total of 20 adult ssRMS patients treated at a single center were retrospectively identified between 2014 and 2023. All patients underwent surgical resection (R0/R1/R2) and received adjuvant chemotherapy (VAC or non-VAC regimens); postoperative radiotherapy was administered in 14 patients. Kaplan-Meier analysis was employed to estimate survival outcomes; log-rank testing was applied to assess between-group differences; and univariate Cox proportional hazards regression was used to calculate hazard ratios (HRs) and 95% confidence intervals. Results: Median follow-up was 35.9 months (95% CI: 28.4-43.3). Median RFS was 37.9 months (95% CI: 12.8-63.1), with 3-year RFS and OS rates of 65.0% and 74.5%, respectively. R0 resection showed a non-significant directional association with improved RFS, and postoperative radiotherapy showed a non-significant directional association with improved OS. Longer chemotherapy duration (≥12 cycles) was associated with improved OS (P = 0.030), although this finding remains exploratory because no deaths occurred in the ≥12-cycle group. Molecular tests were performed in 13 of 20 patients (65%), identifying MYOD1 mutations in 5 patients and ALK unbalanced translocations in 3 patients. Within the molecularly tested subset, progression and death events were observed only among patients harboring MYOD1 mutations or ALK unbalanced translocations. Conclusion: In this adult ssRMS cohort, multimodality perioperative treatment yielded a median RFS of 37.9 months and a 3-year OS rate of 74.5%.Surgical margins, treatment-related factors, and molecular alterations may contribute to outcome heterogeneity in adult ssRMS. MYOD1 mutations and ALK rearrangements identified subsets with more aggressive disease courses, supporting routine molecular profiling in adult ssRMS. These findings are hypothesis-generating given the small cohort size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.